08:00 – 09:15
SPECIAL SESSION: THORACIC SURGERY
Chairs | Dr. Miguel Congregado Hospital Quironsalud Infanta Luisa, Sevilla Dr. Florentino Hernando-Trancho Hospital Clínico San Carlos, Madrid |
| 08:00 - 08:15 | Surgical messages from NADIM II Dr. Ricard Ramos Hospital Clinic Barcelona |
| 08:15 - 08:30 | Surgical messages from CheckMate 816 Dr. Patrick Forde St. James's Hospital, Dublin (Ireland) |
| 08:30 - 08:45 | Perioperative lymph node management in chemo-inmune era Dr. Carlos Gálvez Hospital General Univ. Dr. Balmis, Alicante |
| 08:45 - 09:00 | Long-term results of a real life SECT study: segmentectomy vs. lobectomy for c-stage IA lung cancer Dr. Iker López Hospital Univ. de Donostia |
| 09:00 - 09:15 | Discussion |
09:15 – 09:30
Welcome
| Dr. Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda, Madrid |
09:30 – 11:00
SESSION I: ARTIFICIAL INTELLIGENT (AI) IN LUNG CANCER
| Chairs | Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid Dr. Alberto Ruano Universidad de Santiago de Compostela, A Coruña |
| 09:30 - 09:45 | AI in real-word data: a new horizon Dr. Angela Prelaj Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (Italy) |
| 09:45 - 10:00 | Radiomics in lung cancer applied to diagnosis and prediction Dr. María Jesús Ledesma-Carbayo Universidad Politécnica de Madrid |
| 10:00 - 10:15 | AI in digital pathology and multiplex Immunohistochemistry (IHC) Dr. Sebastian Michels Cologne University Hospital (Germany) |
| 10:15 - 10:30 | Predicting IT with clinical and analytic data Dr. Diego Chowell Mount Sinai, New York (USA) |
| 10:30 - 10:45 | Analyzing mutagenic events in never smokers lung cancer Dr. Marcos Diaz-Gay CNIO, Centro Nacional de Investigaciones Oncológicas, Madrid |
| 10:45 - 11:00 | Discussion |
11:00 – 11:30
Coffee Break
11:30 – 12:45
SESSION II: STAGING AND NSCLC EARLY STAGES
| Chairs | Dr. Monica Antoñanzas Hospital Clínico San Carlos, Madrid Dr. Ignacio Muguruza Hospital Univ. Rey Juan Carlos, Madrid |
| 11:30 - 11:45 | State of art. Neoadjuvant, advuvant and periadjuvant treatments Dr. Ramón Palmero ICO, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona |
| 11:45 - 12:00 | Value of adjuvant therapy after neoadjuvant therapy Dr. Enric Carcereny ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona |
| 12:00 - 12:15 | Predictive factors for pCR in neoadjuvant setting Dr. Tina Cascone MD Anderson Cancer Center, University of Texas (USA) |
| 12:15 - 12:30 | Improving neoadjuvant strategies Dr. Mariano Provencio Hospital Univ. Puerta de Hierro, Majadahonda, Madrid |
| 12:30 - 12:45 | Discussion |
12:45 – 14:05
SESSION III: UPDATES GECP STUDIES AND CONSENSUS
| Chairs | Dr. Pilar Diz Hospital Univ. de León Dr. Alfredo Sánchez Hospital Provincial de Castellón |
| 12:45 - 12:55 | SLCG studies: Early stages NSCLC Dr. Alejandro Olivares Hospital Univ.de Salamanca |
| 12:55 - 13:05 | SLCG studies: Advances stages NSCLC Dr. Laia Vilà Hospital Parc Taulí, Barcelona |
| 13:05 - 13:15 | SLCG studies: Other thoracic tumors and farmacogenomics studies Dr. Carlos Aguado Hospital Clínico San Carlos, Madrid |
| 13:15 - 13:25 | SLCG studies: Registries and database Dr. Karla Medina Hospital Univ. Ntra. Sra. de Candelaria, Santa Cruz de Tenerife |
| 13:25 - 13:35 | Long-term survivors in metastatic lung cancer consensus Dr. Ana Laura Ortega Hospital Univ. de Jaén |
| 13:35 - 13:45 | Multidisciplinary approach for patients with early and locally advanced non-small cell lung cancer (NSCLC). 2nd SLCG consensus Dr. Natividad Martínez Hospital General Univ. Dr. Balmis, Alicante |
| 13:45 - 13:55 | SLCG consensus: Multidisciplinary approach of sexual dysfunction in patients with lung cancer Dr. Vanessa Ospina Hospital Univ. Puerta de Hierro, Majadahonda, Madrid |
| 13:55 - 14:05 | Discussion |
14:05 – 15:30
Lunch
14:05 – 15:30
LUNCH SATELLITE SYMPOSIUM
15:30 – 16:45
SESSION IV: LOCOREGIONAL NSCLC DISEASE
| Chairs | Dr. Hugo Arasanz Hospital Univ. de Navarra Dr. Juan Coves Hospital Son Llàtzer, Palma de Mallorca |
| 15:30 - 15:45 | Induction treatment previously to RT/CT Dr. Virginia Calvo Hospital Univ. Puerta de Hierro, Majadahonda, Madrid |
| 15:45 - 16:00 | Feasibility concomitant immunotherapy and radiotherapy Dr. Reyes Bernabé Hospital Univ. Virgen Macarena, Sevilla |
| 16:00 - 16:15 | Is there a role for SABRT? Dr. Javier Luna Hospital Univ. Fundación Jiménez Díaz, Madrid |
| 16:15 - 16:30 | Treatment strategies for locoregional disease with oncogenic driver Dr. Patricia Iranzo Hospital Univ. Vall d'Hebron, Barcelona |
| 16:30 - 16:45 | Discussion |
16:45 – 18:00
SESSION V: DNA AND LIQUID BIOPSY
| Chairs | Dr. Alberto Cruz Hospital Univ. Puerta de Hierro, Majadahonda, Madrid Dr. Paula Espinosa Hospital Clínic General Univ. de Valencia |
| 16:45 - 17:00 | Pitfalls of liquid biopsy Dr. Atocha Romero Hospital Univ. Puerta de Hierro, Majadahonda, Madrid |
| 17:00 - 17:15 | Assessment of MRD Dr. Margarita Majem Hospital de la Santa Creu i Sant Pau, Barcelona |
| 17:15 - 17:30 | Monitoring response in oncogenic drivers Dr. Manuel Cobo Hospital Regional Univ. de Málaga |
| 17:30 - 17:45 | New developments in liquid biopsy Dr. Valeria Denninghoff GENYO - Centro de Genómica e Investigación Oncológica, Granada |
| 17:45 - 18:00 | Discussion |
18:00 – 19:00
SESSION VI: EGFR DISEASE
| Chairs | Dr. Aitor Azkarate Hospital Univ. Son Espases, Palma de Mallorca Dr. Patricia Cruz Hospital General Univ. de Ciudad Real |
| 18:00 - 18:15 | Treatment decisions in unfrequent mutations Dr. Rafael López Hospital Clínico Univ. de Valladolid |
| 18:15 - 18:30 | Debate: Pros and Cons combination EGFR treatments - Pros Dr. Bartomeu Massutí Hospital General Univ. Dr. Balmis, Alicante |
| 18:30 - 18:45 | Debate: Pros and Cons combination EGFR treatments - Cons Dr. José Luis González Larriba Hospital Clínico San Carlos, Madrid |
| 18:45 - 19:00 | Discussion |